Cited by 78Mangiferin and Mango ExtractsInflammatory Bowel DiseaseNatural Compounds in Disease Treatment

Mangiferin ameliorates colitis by inhibiting IRAK1 phosphorylation in NF-κB and MAPK pathways

Jeong, Jin-Ju, Jang, Se-Eun, Hyam, Supriya R., Han, Myung Joo, Kim, Dong-Hyun·2014·European Journal of Pharmacology

Abstract

Mangiferin, a main constituent of the root of Anemarrhena asphodeloides and the leaves of Mangifera indica, inhibits NF-κB activation in macrophages. Therefore, we investigated effect of mangiferin on 2,3,4-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and its anti-inflammatory mechanism in lipolysaccharide (LPS)- or peptidoglycan-stimulated mouse peritoneal macrophages. Mangiferin inhibited phosphorylation of nuclear factor-kappaB (NF-κB), interleukin-1 receptor-associated kinase 1 (IRAK1), and mitogen-activated protein kinases (MAPK) in peptidoglycan- or LPS-stimulated peritoneal macrophages. Mangiferin in the presence of SN50 inhibited LPS-stimulated NF-κB activation more potently than mangiferin alone. Mangiferin inhibited interaction of fluorescent p-IRAK1 antibody to LPS-stimulated peritoneal macrophages, but increased binding of fluorescent IRAK1 antibody. Mangiferin did not influence interaction of fluorescent LPS to toll-like receptor-4 on the macrophages. Molecular peak of mangiferin bound to IRAK1 was detected in the macrophages by mass analysis. Mangiferin (10 μM) inhibited LPS-stimulated expression of TNF-α, IL-1β and IL-6 by 81.0%, 89.5% and 88.3%, respectively, whereas it increased IL-10 expression by 131.8% compared to LPS-nontreated group. Mangiferin furthermore inhibited colon shortening, macroscopic score, and colonic myeloperoxidase activity in TNBS-induced colitic mice. Mangiferin inhibited TNBS-induced IRAK1 phosphorylation and NF-κB activ…

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2014.06.013

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • MGF exerts protective effects across a broad spectrum of pathological conditions, including inflammatory, neurodegenerative, ocular, renal, cardiovascular, dermatological and infectious diseases.

    “In addition to its well-characterized roles in diabetes and cancer, MGF exerts protective effects across a broad spectrum of pathological conditions. These include inflammatory, neurodegenerative, ocular, renal, cardiovascular, dermatological and infectious diseases (7,36,106,115-118).”
  • MGF activates splenocytes, facilitates plant lectin agglutination and stimulates NK-resistant tumor cell killing by macrophages.

    “MGF activates splenocytes, facilitates plant lectin agglutination and stimulates NK-resistant tumor cell killing by macrophages (105,106).”
  • In murine models, low concentrations of MGF (5-40 mg/ml) enhance the proliferation of splenocytes and thymocytes, whereas higher doses inhibit tumor cell proliferation.

    “Dose-dependent immunostimulatory effects have also been observed in murine models; low concentrations (5-40 mg/ml) enhance the proliferation of splenocytes and thymocytes, whereas higher doses inhibit tumor cell proliferation.”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jeong, J.-J., Jang, S.-E., Hyam, S. R., Han, M. J., & Kim, D.-H.
Affiliations
Kyung Hee University (KR)
Corresponding author
Kim, Dong-Hyun
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2014-10
Volume
740
Pages
652-661
ISSN
0014-2999 (ISSN-L)
OpenAlex
W2038906350
Cited by
78
References
1
Citations by year
2026: 9 · 2025: 6 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 10 · 2016: 10 · 2015: 4 · 2014: 1
FWCI
17.93
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Korea Health Industry Development Institute
  • Ministry of Health and Welfare (HI14C1020)
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
mangiferin, colitis, NF-κB signaling, MAPK signaling, TNBS-induced colitis, peritoneal macrophages, lipopolysaccharide, peptidoglycan, anti-inflammatory activity, cyclooxygenase-2, inducible nitric oxide synthase, TNF-α, IL-1β, interleukin-6, IL-10, TLR4, Anemarrhena asphodeloides, mango
MeSH terms
Animals, Anti-Inflammatory Agents, Colitis, Lipopolysaccharides, Male, Mice, Inbred C57BL, Peptidoglycan, Phosphorylation, Trinitrobenzenesulfonic Acid, Cytokines, NF-kappa B, Macrophages, Peritoneal, Mitogen-Activated Protein Kinases, Xanthones, Interleukin-1 Receptor-Associated Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review